Popular search terms:
Search Results Label
96 results found-
Seqirus Begins Shipping 2017-2018 Influenza Vaccines to the U
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.seqirus.com/...ping-2017-2018-influenza-vaccines -
Seqirus Releases First Shipment for 2019 2020 Season
Seqirus is first to begin shipping its portfolio of seasonal influenza vaccines for the upcoming 2019/20 U.S. influenza season.
https://www.seqirus.com/...rst-shipment-for-2019-2020-season -
Seqirus to Present Data on Pandemic and Seasonal Influenza Vaccines
Seqirus announced it will feature data in 3 presentations and 24 posters on the company's adjuvant and cell-based vaccines for seasonal and pandemic influenza at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore.
https://www.seqirus.com/news/options-x--conference -
Seqirus Presents New Clinical Data Reinforcing MF59
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.seqirus.com/...ew-clinical-data-reinforcing-mf59 -
Anjana Narain to Lead Seqirus Influenza Vaccines Business
CSL Limited today named Anjana Narain, a seasoned leader in vaccines and biopharmaceuticals, as Executive Vice President and General Manager of its Seqirus business, one of the world's largest influenza vaccines providers, effective 1 August. She will replace Gordon Naylor, who announced his retirement earlier this year.
https://www.seqirus.com/...qirus-influenza-vaccines-business -
Seqirus Releases Real-World Data Indicating Significantly Greater
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.seqirus.com/...based-seasonal-influenza-vaccines -
Seqirus Announces U.S. $140 Million Manufacturing Expansion to
The expansion will allow Seqirus to increase capacity for formulation, fill and finish manufacturing of cell-based and adjuvanted influenza vaccines for global markets.
https://www.seqirus.com/...0-million-manufacturing-expansion -
First cell-based quadrivalent influenza vaccine approved for
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.seqirus.com/...luenza-vaccine-approved-in-europe -
JCVI advocates adjuvanted influenza vaccine for patients aged
This decision comes after Public Health England declared that conventional non-adjuvanted influenza vaccines provided little or no protection for adults aged 65 years and over in the 2016-17 flu season in the UK.
https://www.seqirus.com/...ates-adjuvanted-influenza-vaccine -
Seqirus | Partnership Opportunities
Seqirus stands with our partners on the front line of public health. We are the largest fully integrated commercialisation partner in Australia and New Zealand. Learn more.
https://www.seqirus.com/partnering